



ASN Newsletter- July 2024

Save the Date- 2025 Annual Meeting

SAVE THE DATE

**ASN 2025
ANNUAL MEETING**

**JANUARY 17-19 | DALLAS METROPLEX, TX
THE WESTIN IRVING CONVENTION CENTER AT LOS COLINAS**

The [2025 ASN Annual Meeting](#) will be held January 17-19, 2025 at the [Westin Irving Convention Center at Los Colinas](#) in Dallas, TX.

- [Program At A Glance](#)
- Interested in presenting at the Conference? [Click here.](#)
- [Call for Abstracts is now open!](#)

Registration opening soon!



Laszlo Mechtler, MD, FAAN, FEAN, FASN, FAHS, Chief Medical Officer of the DENT Neurologic Institute, Professor of Neurology, Neurooncology, and Neurosurgery, invites you to attend this bi-weekly webinar.

Red Flags in Neuroimaging of Headache, Pt. 2

with
DR. LASZLO MECHTLER

LIVE

DENT
NEUROLOGIC INSTITUTE

AUGUST 2, 2024
12 PM EST

Earn FREE CMEs Via ASN Expertise Webinar Series

Thanks to an incredible partnership between ASN and [Dr. Laszlo Mechtler](#) at the [DENT Neurologic Institute](#), the [ASN Expertise Webinar Series](#) is offered semi-monthly and include presentation, discussion, and open dialogue on imaging cases that align with the ongoing evolution of imaging as a key biomarker in precision medicine and the burgeoning world of neurotherapeutics, informatics, and AI.

The [ASN Expertise Webinar Series](#) is scheduled semi-monthly on Fridays at 12 Noon (EST) and offer **FREE** CME credit to the ASN community.

[Dr. Mechtler](#) will present "Red Flags in Neuroimaging, Part 2" on Friday, August 2 at 12 p.m. For the Zoom link, [click here](#).

UCNS Neuroimaging Certification Exam Application Deadline Approaching

The application period for the [2024 UCNS Neuroimaging Certification](#) is now open with an application deadline of August 1, 2024. The examination will take place the week of February 3-7, 2025. The online application along with complete certification eligibility criteria and the examination content outline are available at www.ucns.org/NIcertification.

There are currently [156 physicians](#) in the United States and Canada who hold the distinction of being UCNS certified in neuroimaging. For additional information or questions related to eligibility or application, contact Todd Bulson, Senior Manager Certification at tbulson@ucns.org or (612) 928-6067.

Centers for Medicare and Medicaid Services (CMS) Releases Proposed Rule for the 2025 Medicare Physician Fee Schedule (PFS)

On July 10, the CMS released its 2025 PFS. The 2025 Medicare conversion factor is set to decrease for the fifth straight year by approximately 2.80 percent from \$33.2875 to \$32.3562. Similarly, the anesthesia conversion factor would be reduced from \$20.7739 to \$20.3340. This cut is largely the result of the expiration of a 2.93 percent temporary update to the conversion factor at the end of 2024 and a 0 percent baseline update for 2025 under the Medicare Access and CHIP Reauthorization Act (MACRA).

Unfortunately, these cuts coincide with ongoing growth in the cost to practice medicine as CMS projects the increase in the Medicare Economic Index (MEI) for 2025 will be 3.6 percent.

To learn more, please refer to these documents:

- [Text of the proposed rule](#)
- [CMS Press Release](#)
- [Physician Payment Schedule Fact Sheet](#)
- [Medicare Shared Savings Program Fact Sheet](#)
- [Quality Payment Program \(QPP\) Fact Sheet](#)

Lilly's Kisunla (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

The U.S. Food and Drug Administration (FDA) [approved a new treatment by Eli Lilly](#). Kisunla (donanemab) is for adults with early symptomatic Alzheimer's disease (AD) which includes mild cognitive impairment (MCI) or mild dementia stage of the disease.

[Kisunla](#) is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 months. Once monthly infusions of 30 minutes reduced amyloid plaques on average of 84% compared to the start of the study.

ASN Brain Death Task Force Survey

The ASN Executive Committee recently approved the endorsement of a survey that was created by the collaborative effort of the Brain Death Task Force put forth by ASN.

["Technical Considerations of Transcranial Doppler for the Assessment of Cerebral Circulatory Arrest in Brain Death: A US Based National Survey"](#) is a survey to describe the current technical considerations of Transcranial doppler (TCD) for the assessment of Cerebral Circulatory Arrest (CCA) in brain death in the United States.

The intended audiences are those practitioners who use TCD as an ancillary test for brain death. We encourage you to [participate in this survey](#).

The American Society of Neuroimaging

Phone: 864-214-6161 • Email: info@asnweb.org

[Manage Your Email Preferences or Unsubscribe](#)